Conflict of Interest Disclosures: Dr Lebwohl reported grants from Eli Lilly during the conduct of the study as well as employment with Mount Sinai; research funding from AbbVie, Arcutis, Avotres, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Clexio, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Johnson & Johnson, Oruka, Pfizer, Sanofi-Regeneron, and UCB; and consulting fees from AbbVie, Added Health, Aikium, Almirall, AltruBio Inc, Alumis, Amgen, Apogee, Arcutis, AstraZeneca, Atomwise, Avotres Therapeutics, Bausch, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celltrion, CorEvitas, Dermavant Sciences, Dermsquared, Edessa, Eli Lilly, Evommune, Facilitation of International Dermatology Education, Forte Biosciences, Galderma, Genentech, Johnson & Johnson, Incyte, LEO Pharma, Mayne Pharmaceuticals, Meiji Seika Pharma, Mindera, Mirium Pharmaceuticals, Meiji Seika Pharma, Moonlake, Novartis, Oruka, Pfizer, Sanofi-Regeneron, Revolo, Seanergy, Strata, Sunpharma, Takeda, Trevi, and Verrica outside the submitted work. Dr Blauvelt reported honoraria from Eli Lilly, UCB, AbbVie, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Bausch Health, Eli Lilly, Incyte, Janssen, Khanda Therapeutics, Leo, Novartis, Oruka, Pfizer, Re-AIM, Recludix, Regeneron, Sanofi, Sun Pharma, Takeda, UCB, and Zai Lab and owning stock in Lipidio and Oruka outside the submitted work. Ms Kartman and Drs Wang, Sun, Somani, Genovese, and Leatherwood reported being an employee of and minor shareholder in Eli Lilly and Company. Dr Gordon reported personal fees from AbbVie, Almriall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dermira, Eli Lilly, Janssen, Novartis, Pfizer, Sun, and UCB as well as grants from AbbVie, Eli Lilly, Celgene, Bristol Myers Squibb, Janssen, Novartis, and UCB during the conduct of the study. Dr Sattar reported personal fees from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly & Company, Gan & Lee, GlaxoSmithKline, Hanmi Pharmaceuticals, Kailera, Mass Medicines, Menarini-Ricerche, Metsera, Novo Nordisk, Pfizer, Regeneron, Roche, UCB Pharma, and Bio as well as grants from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics outside the submitted work. Dr Puig reported personal fees from Lilly during the conduct of the study as well as personal fees from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Horizon, Johnson & Johnson Innovative Medicine, Leo Pharma, Samsung Bioepis, Sandoz, Sun Pharma, Takeda, and UCB; grants from UCB, Johnson & Johnson, and Almirall; and nonfinancial support from Pfizer and Novartis outside the submitted work. Dr Merola reported personal fees from Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, AbbVie, Eli Lilly, Moonlake, Novartis, Janssen, Oruka, UCB, Sanofi, Regeneron, Sun Pharma, Galderma, Biogen, and Pfizer outside the submitted work. Dr Siu and Ms Leung reported being employees of Eli Lilly during the conduct of the study. Drs Rueda and Cardoso reported personal fees from Eli Lilly during the conduct of the study and outside the submitted work. Dr Armstrong reported grants from Alumis, Bristol Myers Squibb, Galderma, Janssen, Novartis, and Takeda and personal fees from AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant Sciences, Eli Lilly and Company, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi, UCB, Incyte, Ortho Derm, and Boehringer Ingelheim outside the submitted work. Dr Strober reported personal fees from Eli Lilly, AbbVie, Alumis, Almirall, Amgen, Apogee, Arcutis, Bristol Myers Squibb, CorEvitas, Dimagi, Immunovant, Johnson & Johnson, Leo, Eli Lilly, Neurocrine, Novartis, Oruka, Meiji Seika Pharma, Protagonist, Pfizer, UCB Pharma, Regeneron, Sanofi-Genzyme, selectION, and Takeda; stock options in Mindera Health and selectION; speaker fees from AbbVie, Arcutis, Eli Lilly, Incyte, Johnson & Johnson, Regeneron, and Sanofi-Genzyme; service as a scientific codirector for CorEvitas Psoriasis Registry; and service as an investigator for CorEvitas Psoriasis, GPP Registries, Oruka, and Incyte outside the submitted work. No other disclosures were reported.
PubMed
